Tryptamine Therapeutics
Tryptamine Therapeutics (now Entropy Neurodynamics) is a clinical-stage biotech developing TRP-8803, an IV psilocin formulation for psychedelic-assisted treatment of fibromyalgia, IBS, and eating disorders. It is pre-revenue and listed on the ASX (ENP).
- Company typePublic
- Founded2019
- HeadquartersKelowna, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Tryptamine Therapeutics does
Tryptamine Therapeutics, now operating as Entropy Neurodynamics (ASX: ENP; CNSX: TRYP), is a clinical-stage biotechnology company developing patented formulations for the administration of psilocin alongside psychedelic-assisted therapy. Founded in 2019 and headquartered in East Hawthorn, Victoria, Australia, the company's lead program is TRP-8803, an IV infusion of psilocin — the active metabolite of psilocybin — designed to address limitations of orally administered psilocybin. Specifically, TRP-8803 reduces treatment time from 8–10 hours to approximately 2 hours and eliminates inter-patient dose variability by enabling rapid initiation and termination of the psychedelic experience. The platform also incorporates synthetic psilocybin administered with psychotherapy.
The company's pipeline targets neuropsychiatric indications with high unmet need, including fibromyalgia, irritable bowel syndrome (IBS), and eating disorders (particularly binge eating disorder), with additional research interest in depression, pain, and obsessive-compulsive disorders. The IP strategy comprises six provisional patent families covering formulation, infusion methods, biomarkers, and therapeutic applications. Leadership includes CEO Jason Carroll (formerly of J&J/Janssen/Bristol-Myers Squibb), President & CSO Jim Gilligan, PhD, and a Scientific Advisory Board chaired by Robin Carhart-Harris (founder of Imperial College's Centre for Psychedelic Research).
The business model is contingent on future regulatory approval: the company is pre-revenue, with monetization expected via pharmaceutical product sales of TRP-8803 through hospital/clinic dispensing and specialist prescriber networks for psychedelic-assisted psychotherapy. Operating geographies are Australia-based, though clinical trials are conducted at specialized research sites globally. The company has funded operations through six equity/debt rounds between 2021 and 2024 (approximately AUD $15.5M cumulative) and Australian Government R&D Tax Incentive refunds, including $1.73M AUD in FY25.
Tryptamine Therapeutics firmographics
Firmographics- Name
- Tryptamine Therapeutics
- Legal name
- Entropy Neurodynamics
- Website
- https://tryptherapeutics.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tryptamine Therapeutics (now Entropy Neurodynamics) is a clinical-stage biotech developing TRP-8803, an IV psilocin formulation for psychedelic-assisted treatment of fibromyalgia, IBS, and eating disorders. It is pre-revenue and listed on the ASX (ENP).
- Ownership category
- akta.pro rank
Tryptamine Therapeutics industry classification
Industry- Product category
- Clinical-Stage Psychedelic Therapeutics
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Eating Disorder Treatment Programs (HLAFACAK)
Keywords
Where Tryptamine Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Kelowna
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Tryptamine Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Product Sales: Revenue expected from sale of patented IV psilocin formulation (TRP-8803) upon regulatory approval for treatment of neuropsychiatric disorders including fibromyalgia, IBS, and eating disorders.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Tryptamine Therapeutics product offering
Product offeringCore offering
Tryptamine Therapeutics (now operating as Entropy Neurodynamics) is a clinical-stage biotechnology company developing patented formulations for the administration of psilocin and synthetic psilocybin alongside psychedelic-assisted psychotherapy. Its lead program, TRP-8803, is an IV infusion of psilocin (the active metabolite of psilocybin) that targets fibromyalgia, irritable bowel syndrome (IBS), and eating disorders such as binge eating disorder. The IV delivery approach is designed to reduce treatment time from 8-10 hours to approximately 2 hours while eliminating dose variability between patients.
Product overview
Entropy Neurodynamics (formerly Tryptamine Therapeutics) is a clinical-stage biotechnology company developing a portfolio of psychedelic-assisted therapies. The core offering consists of TRP-8803, an IV infusion formulation of psilocin (the active metabolite of psilocybin), alongside synthetic psilocybin administered with psychotherapy. The company's lead programs focus on fibromyalgia, irritable bowel syndrome (IBS), and eating disorders (particularly binge eating disorder). The proprietary IV delivery approach reduces treatment duration from 8-10 hours to approximately 2 hours while providing precise dosing control.
Differentiator
Problem solved
Functional benefit
Products and services
- TRP-8803 (IV Psilocin Formulation)
Quantifiable outcome
- Treatment time reduced from 8-10 hours to 2 hours
- +1 more outcomes
Companies that use Tryptamine Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Tryptamine Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Tryptamine Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Top-tier Universities and InstitutionscoreThe company actively collaborates with top-tier universities and institutions to accelerate discovery and delivery of psychedelic therapies. Leadership team combines deep scientific expertise with proven operational execution across biotech, pharma, and clinical research.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Tryptamine Therapeutics competitors and assessment
Company assessmentDirect peers
- Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. NASDAQ-listed with substantially greater resources, competing directly in the psychedelic neuropsychiatric space with overlapping mechanism and clinical-stage assets.
- Cybin: Clinical-stage psychedelic therapeutics company developing psilocybin-based therapies for depression and other mental health conditions. Direct competitor pursuing the same psilocybin/psilocin class for neuropsychiatric indications.
- GH Research: Clinical-stage biopharmaceutical company developing mebufotenin and other 5-HT2A agonists for psychiatric and neurological disorders. Closest mechanistic peer to Entropy's psilocin program with overlapping serotonin-receptor targeting.
- Gilgamesh Pharmaceuticals: Clinical-stage psychedelic medicine company developing novel neuroplastogens and psychedelic-inspired therapeutics for mental health. Recently acquired by AbbVie, validating large-pharma interest in the space and competing in overlapping indications.
- atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health disorders including depression, anxiety, and PTSD. Competes directly in psychedelic neuropsychiatric drug development with broader pipeline.
- Beckley Psytech: Clinical-stage psychedelic medicine company developing psilocybin and other psychedelic compounds for neuropsychiatric conditions. Backed by atai Life Sciences; competes with overlapping psychedelic drug development programs.
- Mind Medicine (MindMed): Clinical-stage psychedelic medicine company developing LSD and psilocybin-based therapies for anxiety, ADHD, and other mental health indications. Direct competitor pursuing overlapping psychedelic mechanisms for neuropsychiatric conditions.
Emerging players
- Delix Therapeutics: Clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for depression and other CNS conditions. Adjacent competitor focused on psychedelic-inspired non-hallucinogenic compounds targeting similar neuropsychiatric indications.
- Lobe Sciences: Clinical-stage life sciences company developing psychedelic-inspired therapeutics for neurological and mental health conditions. Smaller emerging peer with overlapping psychedelic medicine focus, comparable in scale to Entropy.
Broad incumbents
- Sage Therapeutics: Commercial-stage CNS biopharmaceutical company with Zurzuvae (zuranolone) approved for postpartum depression. Established CNS player providing context for neuropsychiatric drug development economics and partnership precedents.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Tryptamine Therapeutics social profiles
Digital presenceTryptamine Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tryptamine Therapeutics leadership team
Management profileNumber of profiles
Profiles21 records
Tryptamine Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tryptamine Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tryptamine Therapeutics
What does Tryptamine Therapeutics do?
Tryptamine Therapeutics (now operating as Entropy Neurodynamics) is a clinical-stage biotechnology company developing patented formulations for the administration of psilocin and synthetic psilocybin alongside psychedelic-assisted psychotherapy. Its lead program, TRP-8803, is an IV infusion of psilocin (the active metabolite of psilocybin) that targets fibromyalgia, irritable bowel syndrome (IBS), and eating disorders such as binge eating disorder. The IV delivery approach is designed to reduce treatment time from 8-10 hours to approximately 2 hours while eliminating dose variability between patients.
Is Tryptamine Therapeutics a public or private company?
Tryptamine Therapeutics is a public company. It is classified as public and is currently operating.
When was Tryptamine Therapeutics founded?
Tryptamine Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is Tryptamine Therapeutics based?
Tryptamine Therapeutics is headquartered in Kelowna, Canada, in the North America region.
How does Tryptamine Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Tryptamine Therapeutics's main competitors?
Direct peers on record are Compass Pathways, Cybin, GH Research, Gilgamesh Pharmaceuticals, atai Life Sciences, Beckley Psytech and Mind Medicine (MindMed). Emerging players are Delix Therapeutics and Lobe Sciences. Sage Therapeutics is listed as a broad incumbent.
Does Tryptamine Therapeutics have an API?
No public API is recorded for Tryptamine Therapeutics.
What industry is Tryptamine Therapeutics in?
Tryptamine Therapeutics's product category is Clinical-Stage Psychedelic Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAFACAK, Eating Disorder Treatment Programs. Its SIC code is 8731.